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Abstract
Background: Seven genes involved in folate metabolism are located on chromosome 21. Previous studies have shown that
folate deficiency may contribute to mental retardation in Down’s syndrome (DS).
Methodology: We investigated the effect of oral folate supplementation (daily dose of 1.060.3 mg/kg) on cognitive
functions in DS children, aged from 3 to 30 months. They received 1 mg/kg leucovorin or placebo daily, for 12 months, in a
single-centre, randomised, double-blind study. Folinic acid (leucovorin, LV) was preferred to folic acid as its bioavailability is
higher. The developmental age (DA) of the patients was assessed on the Brunet-Lezine scale, from baseline to the end of
treatment.
Results: The intent-to-treat analysis (113 patients) did not show a positive effect of leucovorin treatment. However, it
identified important factors influencing treatment effect, such as age, sex, and concomitant treatments, including thyroid
treatment in particular. A per protocol analysis was carried out on patients evaluated by the same examiner at the
beginning and end of the treatment period. This analysis of 87 patients (43 LV-treated vs. 44 patients on placebo) revealed a
positive effect of leucovorin on developmental age (DA). DA was 53.1% the normal value with leucovorin and only 44.1%
with placebo (p,0.05). This positive effect of leucovorin was particularly strong in patients receiving concomitant thyroxin
treatment (59.5% vs. 41.8%, p,0.05). No adverse event related to leucovorin was observed.
Conclusion: These results suggest that leucovorin improves the psychomotor development of children with Down’s
syndrome, at least in some subgroups of the DS population, particularly those on thyroxin treatment.
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Introduction
The symptoms of Down’s syndrome (DS) result from a trisomy of
chromosome 21 [1,2]. A gene dosage effect [3,4], resulting from the
presence of three chromosomes 21, rather than the usual two, is
responsibleforsymptomsandmildtoseverementalretardation[5,6].
T h e r ei sc u r r e n t l yn oe f f e c t i v ew a yt or e d u c et h i sg e n ed o s a g ee f f e c t .
However, some of the metabolic disturbances have been studied and
could be targeted pharmacologically [2,7]. The correction of these
dysfunctions by treating DS patients with active molecules may
improve the mental condition and quality of life of these patients.
Folate deficiency is known to cause neurological, psychiatric
and cognitive disorders [8,9,10,11,12,13,14,15,16], that can be
reversed by folic acid administration [16,17,18]. DS probably
involves either folate deficiency or defective folate use. Indeed, at
least seven genes (SCL19A1, FTCD, GART, CBS, PRMT2,
N6AMT1, DNMT3L with HGCN ID numbers: 10937, 3974,
4163, 1550, 5186, 16021, 2980, respectively) related to folate
metabolism are located on chromosome 21 [19,20]. The over-
expression of these genes has been observed and causes a cascade
of metabolic disturbances: low concentrations of folates, methio-
nine, homocysteine, S-adenosyl methionine and serine and high
levels of cysteine, cystathionine and methylated DNA (Figure 1)
[7,14,21,22,23]. These disturbances partly account for the
macrocytosis [24], glossitis and methotrexate hypersensitivity
usually observed in these patients [25,26,27,28], which can be
partially corrected by folic acid treatment [27]. One previous study
reported that folate treatment might improve the psychomotor
development of DS patients [29,30]. However, this study did not
meet current standards for clinical trials and other studies did not
confirm this finding [31,32,33]. Many DS children have since
received empirical folate treatment.
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8394We carried out a one-year, double-blind, placebo-controlled trial
to assess the effect of folate supplementation on psychomotor
development in young DS patients (3 months to 30 months of age).
The registration number of this clinical trial was NCT00294593
(http://clinicaltrials.gov). Folinic acid/leucovorin (LV), also known
as N5-formyl tetrahydrofolate (THF), was preferred to folic acid as
it is already reduced. It can therefore enter the cytoplasm via the
reduced folate carrier system (RCF), encoded by a gene (SLC19A1)
located on chromosome 21. Leucovorin also bypasses the enzymatic
steps of folic acid activation by DHFR, and is transformed by
MTHFS and MTHFD1. Furthermore,leucovorin crosses the blood
brain barrier more efficiently than folic acid resulting in greater
bioavailability to neurons [34]. The clinical protocol took several
factors potentially affecting developmental quotient into account,
including age, sex and concomitant treatments. Hypothyroidism,
which is frequent in DS patients, was carefully assessed as it may
strongly affect mental development [35,36].
Materials and Methods
Study Design
In this randomised, double-blind, placebo-controlled, single-
centre clinical trial of leucovorin (LV), patients were randomised
to two groups of equal size, one receiving placebo and the other
leucovorin (LV 1 mg/kg daily per os). Treatment lasted 12
months, during which patients attended three scheduled visits: at
inclusion (V1), after 6 months (V2) and after 12 months (V3)o f
treatment. All three visits included clinical examination, develop-
mental evaluation and blood sampling (complete blood count,
ferritin determination, thyroid check). Patients were assessed by a
team of health professionals, including four physicians and six
psychologists. The developmental test (main criterion) had to be
carried out by the same psychometric examiner in each case. The
protocol for this trial and the CONSORT checklist are available
as supporting information (see Protocol S1 and Checklist S1). The
study was conducted in accordance with the Helsinki Declaration
and its amendments. It was approved by an institutional review
board and by the French health authorities (AFSSaPS, CCPPRB
Saint-Germain-en Laye). All parents gave written informed
consent for the participation of their child. The informed consent
statement and the informed consent form are provided as
supporting information (see Informed Consent S1).
Target Population and Inclusion Criteria
The inclusion criteria were: children aged 3 to 30 months, with
complete, homogeneous trisomy 21. Patients had to weigh more
than 4 kg, and be able to undergo assessment with the revised
Brunet-Lezine psychometric scale (BLS). Patients with a history of
Figure 1. Folate metabolic pathways and methylation cycle. Gene names are shown in italics and according to the HGNC approved names.
Genes in boxes are located on chromosome 21. Abbreviations used are: DHF: dihrofolate; THF: tetrahydrofolate; 5,10-CH2 THF: N5,N10-methylene
THF; 5,10-CH THF: N5,N10-methenyl THF; 5-CH3 THF: N5-methyl THF; GAR: glycinamide ribonucleotide; FGAR: formyl-GAR; GSH: reduced form of
glutathione; GSSG: oxidised form of glutathione; ROS: reactive oxygen species.
doi:10.1371/journal.pone.0008394.g001
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evaluations of treatment efficacy, such as epilepsy or unstable
hypothyroidism, were excluded.
Sample Size
The sample size required was determined with nQuery
AdvisorH software (Statistical Solutions, Cork, Ireland). Based on
internal unpublished data and a two-sided test with 80 percent
power to detect a difference significant at the 5% level, with a
standard deviation of 0.4, each group had to be composed of 47
patients for the detection of an expected 33% difference. Taking
into account the probable frequency of non-evaluable patients, we
planned to include 60 patients in each group.
Outcome Measures
The primary endpoint (efficacy variable) was increase in global
developmental age (DA), calculated as the following ratio: months
acquired/months of follow-up. The revised Brunet-Lezine scale
was used to assess developmental age [37,38]. This scale of
psychomotor development in early childhood investigates four
fields of childhood development: (i) ‘posture’, (ii) ‘co-ordination’,
(iii) ‘language’ and (iv) ‘sociability’, each with a corresponding
subscore. The global DA score is derived from these four
subscores. This scale has been validated for children of the
general population with a developmental age of 2 to 30 months
[38,39]. It has been adapted for French populations and resembles
the Bayley or Griffiths scales used in other countries.
Safety
The safety of the treatment studied was assessed by recording
adverse clinical events and carrying out biological assays at each
visit. Any side effect arising during the trial, whether drug-related
or not, was regarded as an adverse event and recorded. Sealed
emergency decoding envelopes were available. Biological assays
were analysed using paediatric reference ranges [40].
Treatment and Randomisation
The drug was produced as 5 mg capsules, which had to be
opened for administration—in a single intake—at breakfast. The
active drug was administered as the pentahydrated calcium salt of
leucovorin, to obtain a daily dose of 1.060.3 mg/kg. Drug
compliance was assessed by counting the pills. The placebo and
active capsules were obtained from the manufacturer of the drug
(FolinoralH, Laboratoires Therabel Lucien Pharma, Levallois-
Perret, France). Parents were asked not to administer any other
folate-containing drugs to their children. Concomitant treatment
was also minimised and noted in the case report form. Patients
were assigned to a treatment by the random permuted block
method (1:1 ratio). Eligible patients were recruited as and when
they were referred by participating physicians over a two-year
period. An independent contract research organisation (LC2,
Lyon, France) performed this operation and the randomisation list
was not made available until the data were frozen. Thus, all
investigators were blind to treatment assignment.
Plan for Statistical Analysis
Data were encoded and input twice for quality assurance
purposes. No interim analysis was planned. Data were frozen after
double checking, recorded on a CD-Rom, and deposited at a
lawyer’s office before the code was broken. Data for patients
who withdrew from the study early were analyzed for tolerability
and, if possible efficacy. Demographic characteristics, clinical and
biological tolerability and efficacy were analyzed by classical
methods (Student’s t test), using SPSS
 software (SSPS Inc.
Chicago, IL, USA). A test of non linearity was planned for the
Brunet-Lezine scale, using the data of children examined by the
same person at all three evaluation points, V1, V2 and V3. We
tested the nullity of the coefficient c in the following equation: BL
Global score=constant+ai+b6date+c6date
2, with ai, the effect
on patient #i, b the date effect and c the non linear date effect.
The 3 evaluation points, V1, V2 and V3, were coded 21, 0 and 1,
respectively. Once rejected the hypothesis of non-linearity of
Brunet-Lezine scale over time, the Developmental Age (DA) was
used to perform further statistical analysis.
In an exploratory way, a principal component analysis was
carried out with SPAD
 software (Coheris, Courbevoie, France)
[41]. This interesting method gives an axis that better summarizes
the four DA variables (Global DA, Postural DA, Language DA,
Coordination DA and Sociability DA). By projecting barycentres
of the patients with same characteristics on the first axis, we
identified influential cofactors. The factors included in the study
were: leucovorin treatment, age at start of treatment, sex, body
weight at start of treatment, developmental age at start of
treatment (assessed by the Brunet-Lezine scale), treatment
duration, thyroid treatment, psychometric examiner. Once the
influential factors had been identified, several models of analysis of
variance (ANOVA) were tested for treatment efficacy. We kept the
ANOVA model that had good quality criteria (high variability of
the Global DA explained by the model and low probability of
simultaneous nullity of coefficients).
Results
Patient Population
All DS patients were recruited and included at the Jerome
Lejeune Institute (Paris, France). Follow-up of the last participant
ended 12 months later. In total, 117 patients were included in the
trial (Figure 2). No patient withdrew due to treatment effects. Four
of the 117 patients included withdrew early without an assessment
of treatment efficacy. Thus 113 patients were included in the
demographic and baseline description, and the safety and
intention-to-treat analysis of efficacy. Evaluation by the same
psychometric examiner before and after treatment, as required by
the protocol, was not possible for 26 of the 113 patients (23.0%).
The other 87 patients were included in an additional per protocol
analysis of efficacy (Figure 3). This analysis took into account, for
each child, the first and last evaluations by the same psychometric
examiner (V12V3 if possible, otherwise V12V2 or V22V3), after
the linearity of the judgment criteria between V12V2 and V22V3
had been checked (data not shown).
Demographic and Baseline Description
The baseline description recorded the medical history of
patients, including Down’s syndrome-related diseases in particular:
cardiac abnormalities (persistent common atrioventricular canal,
etc), digestive malformations (atresia), hypothyroidism requiring
thyroxin treatment, ophthalmologic diseases (nystagmus, strabis-
mus, cataracts). No history of haematological conditions was
reported. The main demographic characteristics of the enrolled
patients did not differ between the groups (Table 1). These
demographic and baseline characteristics were similar in the per
protocol population (Table 2).
Brunet-Lezine Scale Linearity
The psychometric scale used has been validated in a population
of normal French children; the score obtained should increase
linearly from 3 months to 30 months of age [38]. We checked the
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evaluated three times (V1, V2 and V3) by the same psychologist.
We obtained the following probabilities of nullity for each
coefficient: probability (constant=0)=0, probability (b=0)=0,
probability (c=0)=0.698. We therefore rejected the hypothesis of
non-linearity for BL global score.
Efficacy Analysis
The intention-to-treat analysis (113 patients) revealed no greater
positive effect of LV than of placebo on change in global DA
(52.1% of normal DA vs. 51.5%, respectively). However, the per
protocol multivariate analysis carried out on the 87 patients
examined by the same person at the start and end of the trial
showed that leucovorin probably enhanced DA. Children who
received LV displayed a greater increase in DA (52.6%) than those
treated with a placebo (42.8%, p=0.046) (Figure 3). Cofactors
were identified by principal component analysis on patients, for
global DA score and the four subscores (posture, co-ordination,
sociability, language). As we observed that the first axis was
strongly correlated with Global DA (0.99), we concluded that it
separated well children with high Global DA values from those
with low Global DA values. The cofactors most strongly linked to
the first axis (and thus global DA) were leucovorin treatment, age
at start of treatment, sex and concomitant thyroxin treatment.
These factors and their interactions with leucovorin treatment
were thereafter assessed by analysis of variance (Table 3). The
‘‘age*thyroxin treatment’’ interaction cannot be studied because
young children did not receive thyroxin treatment and the
‘‘sex*age’’ and ‘‘sex*thyroxin’’ interactions were not significant
when added in the model.
Figure 2. Flow chart of participants in the clinical trial. N=number of patients. Not eligible: patients with no efficacy and safety data after V1.
Early premature V1 discontinuation: patients with no efficacy and safety data after V1. Late premature V2 discontinuation: patients not evaluated after
V2 (6 months). Per protocol analysis: patients assessed by the same psychometric examiner during at least 2 visits. Major protocol violation: patients
not assessed by the same psychometric examiner at 2 consecutive visits. Completed: patients without protocol violation and with 12 months of
efficacy and safety data.
doi:10.1371/journal.pone.0008394.g002
Figure 3. Effect of leucovorin treatment on change in global
developmental age (DA). DA was measured for the patients receiving
placebo or LV, in the per protocol population (87 patients) and as a
function of a thyroxin treatment (N=number of patients, % change in
developmental age with respect to a non-DS age-matched population).
doi:10.1371/journal.pone.0008394.g003
Leucovorin and Down’s Syndrome
PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8394Patients who received LV displayed a greater increase in DA
evolution (53.1%) than those on placebo (44.4%, p=0.031)
(Figure 3). Means were adjusted, to equilibrate the effect of the
model. Two quality indicators showed that the selected statistical
model for change in global DA was acceptable. The probability of
simultaneous nullity of factors and interactions was 0.0007 and the
Table 1. Demographic and baseline characteristics in the intention-to-treat group (113 patients).
Characteristics n LV group Placebo group
Sex male/Female, n [%] 113 31 [55.4]/25 [44.6] 29 [50.9]/28 [49.1]
Birth characteristics, mean6SD
1
Weight (g) 112 2.9560.54 3.0760.57
Length (cm) 107 47.662.5 47.862.3
OFP
2 (cm) 103 32.961.7 33.261.4
Previous medical history, n [%]
Neonatal 108 6 [11.1] 8 [14.8]
Cardiovascular 112 25 [45.5] 24 [42.1]
Digestive 112 5 [9.1] 8 [14.0]
Thyroid 112 14 [25.5] 10 [17.5]
Ophtalmologic 112 5 [9.1] 8 [14.0]
General characteristics V1
3, mean6SD [range]
Age (months) 113 14.468.1 [2.9–30.7] 13.768.9 [2.7–30.9]
Weight (kg) 113 8.662.1 [4.5–14.0] 8.161.9 [4.81–12.00]
Height/length (cm) 113 72.468.0 [56.0–85.5] 71.468.6 [56.0–89.0]
OFP (cm) 113 43.462.5 [38.5–47.5] 43.262.3 [37.0–47.3]
Medical problems V1, n [%]
General 113 36 [64.3] 33 [57.9]
Neurological 113 34 [60.7] 31 [54.4]
Behavioural 113 7 [12.5] 7 [12.3]
BL
4 age V1, mean6SD [range] (months)
Postural 113 8.664.6 [1.0–20.0] 8.465.0 [2.0–20.0]
Co-ordination 113 8.864.7 [2.0–20.0] 8.064.7 [1.3–18.0]
Language 113 8.164.1 [1.5–20.0] 7.764.2 [1.5–18.0]
Sociability 113 8.565.0 [1.5–18.5] 8.265.0 [2.0–18.5]
Global 113 8.664.5 [1.7–18.5] 8.164.6 [1.8–18.2]
DQ
5 V1, mean6SD [range] (%) 113 62.6613.4 [29.1–96.9] 63.4613.5 [29.5–97.8]
Biology V1, mean6SD
Red cells (10
6/mm
3) 101 4.4360.46 4.3660.33
Haemoglobin (g/100 ml) 100 12.7561.31 12.6260.86
Haematocrit (%) 101 38.2963.96 37.5762.69
MCV
6 (m
3) 101 86.5464.59 86.1964.26
Platelets (10
3/mm
3) 100 3786116 4026114
White cells (mm
3) 101 743762369 715762149
Neutrophils (mm
3) 101 313561720 295361395
Lymphocytes( m m
3) 101 350161288 340661298
Monocytes (mm
3) 101 5756231 6056369
Ferritin (mg/l) 90 50.61666.55 47.63656.54
TSH
7 (mU/l) 102 3.9661.99 3.3661.96
Free T4
8 (pmol/l) 94 15.4463.14 15.2862.80
1Standard deviation.
2Occipito-frontal perimeter.
3inclusion visit.
4Brunet-Lezine.
5Developmental Quotient.
6Mean corpuscular volume.
7Thyroid-stimulating hormone.
8Thyroxin.
doi:10.1371/journal.pone.0008394.t001
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There was a significant interaction between LV treatment and
concomitant thyroxin treatment (p=0.035), with a DA of 59.5%
recorded for patients receiving both leucovorin and thyroid
treatment, versus only 41.8% for those receiving thyroid treatment
only. The same model was computed for the four psychometric
Table 2. Demographic and baseline characteristics in the per protocol group (87 patients).
Characteristics n LV group Placebo group
Sex male/Female, n [%] 87 23 [53.5]/20 [46.5] 25 [56.8]/19 [43.2]
Birth characteristics, mean6SD
1
Weight (g) 86 2.9660.58 3.1860.56
Length (cm) 83 47.662.8 48.162.3
OFP
2 (cm) 80 32.961.9 33.361.5
Previous medical history, n [%]
Neonatal 83 5 [11.9] 7 [17.1]
Cardiovascular 87 22 [51.2] 17 [38.6]
Digestive 87 3 [7.0] 8 [18.2]
Thyroid 87 13 [30.2] 10 [22.7]
Ophtalmologic 87 4 [9.3] 7 [15.9]
General characteristics V1
3, mean6SD [range]
Age (months) 87 14.768.1 [2.9–28.4] 13.969.0 [2.7–30.9]
Weight (kg) 87 8.7662.10 [4.77–14.00] 8.2261.92 [4.81–12.00]
Height/length (cm) 87 72.767.9 [56.0–84.5] 71.768.4 [57.5–89.0]
OFP (cm) 87 43.462.5 [38.5–47.5] 43.562.3 [37.0–47.3]
Medical problems V1, n [%]
General 87 25 [58.1] 26 [59.1]
Neurological 87 24 [55.8] 25 [56.8]
Behavioural 87 5 [11.6] 7 [15.9]
BL
4 age V1, mean6SD [range] (months)
Postural 87 8.864.5 [1.0–20.0] 8.565.0 [2.0–20.0]
Co-ordination 87 9.064.7 [2.0–19.0] 8.164.7 [1.3–18.0]
Language 87 8.564.2 [1.5–20.0] 7.864.2 [2.0–18.0]
Sociability 87 9.065.1 [2.0–18.5] 8.164.8 [2.0–18.5]
Global 87 8.964.5 [1.7–17.6] 8.264.5 [1.8–18.2]
DQ
5 V1, mean6SD [range] (%) 63.4613.0 [29.1–91.3] 63.7613.8 [29.5–97.8]
Biology V1, mean6SD
Red cells (10
6/mm
3) 76 4.4460.45 4.3360.32
Haemoglobin (g/100 ml) 76 12.8261.21 12.5060.76
Haematocrit (%) 76 38.4063.53 37.3262.52
MCV
6 (m
3) 76 86.6163.91 86.2964.35
Platelets (10
3/mm
3) 76 3716106 4016123
White cells (mm
3) 76 718662172 722162237
Neutrophils (mm
3) 76 290861436 296861516
Lymphocytes( m m
3) 76 348661388 348361333
Monocytes (mm
3) 76 5826217 5806270
Ferritin (mg/l) 67 46.61657.91 49.35661.36
TSH
7 (mU/l) 78 4.0662.05 3.4262.11
Free T4
8 (pmol/l) 73 15.7463.10 15.3262.67
1Standard deviation.
2Occipito-frontal perimeter.
3inclusion visit.
4Brunet-Lezine.
5Developmental Quotient.
6Mean corpuscular volume.
7Thyroid-stimulating hormone.
8Thyroxin.
doi:10.1371/journal.pone.0008394.t002
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vs. 42.18%, p=0.019). It had a more pronounced effect on ‘co-
ordination’ DA when the child was treated concomitantly with
thyroxin (66.0% vs. 38.02%, p=0.035). Similar trends were
observed, but were not statistically significant, for ‘language’,
‘posture’ and ‘sociability’. These results were obtained when the
population was split into five age groups. However, similar levels of
significance were observed with two, three or four classes of age.
Finally, mean change in global DA was greater for girls than for
boys (53.6% versus 43.9%, p=0.006) and girls showed larger
improvements in ‘language’ and ‘sociability’ than boys (50.6% vs.
37.8%, p=0.008 and 71.1% vs. 49.9%, p=0.002, respectively).
Compliance and Safety
Compliance was good, with patients taking 91% of their
prescribed treatment. The mean duration of treatment was
358644 days. DS patients present many common early childhood
diseases, all of which were considered adverse events. We therefore
recorded numerous concomitant treatments and adverse events.
However no serious adverse event or drug-related adverse event
was reported. For the 113 patients with safety data, a mean of 3.34
adverse events per patient occurred in the treated group, versus
3.84 in the placebo group (p.0.05) (Table 4). For the concomitant
treatments, including drugs and rehabilitation, a mean of 7.8
treatments per patient were administered in the LV group, vs. 8.6
in the placebo group (p.0.05). No significant difference between
therapeutic classes (acute toxicity class; ATC) was found (Table 5).
No LV-related biological adverse events occurred during treat-
ment and mean changes in biological data were similar between
groups.
Discussion
Folates, including folic acid, in particular have been adminis-
tered to DS patients based on a preliminary study conducted some
time ago and not meeting current protocol standards [29,30].
Assessments of the efficacy and safety of this treatment were
required. Our intention-to-treat analysis showed no positive effect
of leucovorin. However, the per-protocol analysis of a restricted
group examined by the same psychologist at the beginning and
end of trial revealed a positive effect of leucovorin. In the per-
protocol analysis, the DA of DS children was significantly higher
on leucovorin treatment than on placebo (53.1% vs. 44.4%,
p=0.031) (Figure 3). The per-protocol analysis also identified
several cofactors, including thyroid treatment. DS patients
receiving leucovorin and thyroxin treatment had a DA of
59.7%, whereas those receiving thyroxin only had a DA of
40.3% (p=0.041).
The choice to use folinic acid/leucovorin rather than folic acid
is debatable. Leucovorin may be a good alternative to folic acid
because it is transported by the RFC (SLC19A1 gene) and
efficiently transformed into 5,10-CH2 THF and 5-CH3 THF,
which may be reduced by three methyl transferases—DNMT3L,
PRMT2, N6AMT1—and by CBS activity (Fig. 1). Several studies
have reported this molecule to have a higher bioavailability than
folic acid [17,34,42]. No side effect of this drug was observed,
despite its use at more than 10 times the RDA. Studies on folic
acid have also reported an absence of adverse events [16]. As some
positive effects were detected in our patients, we believe this dose
of LV to be appropriate and safe for folate supplementation.
We also hypothesized that age at the start of folate
supplementation might be important, as young neurons may be
more sensitive to treatment, resulting in more efficient rescue from
Table 3. Factors influencing global developmental age in
patients of the per protocol population (N=87).
Factor p Significance
Degrees of
freedom
Treatment with LV 0.0305 * 1
Sex 0.0064 * 1
Age (5 classes) 0.008 * 4
Thyroid treatment 0.3756 NS 1
LV x sex 0.4039 NS 1
LV x age 0.3016 NS 4
LV x thyroid treatment
# 0.0348 * 1
The p values for each factor or interaction obtained in analysis of variance are
shown. There were n21 degrees of freedom, with n the number of possible
levels of the factor.
#Patients that received both LV and Thyroxin treatment had a DA significantly
higher than the other patients.
doi:10.1371/journal.pone.0008394.t003
Table 4. Adverse events occurring in patients during the
study period (113 patients).
Disease category LV (56) Placebo (57)
Infectious diseases 26 41
Hypothyroidism 1 1
Excitement, agitation 5 2
Eye and ear disease 23 31
Respiratory system diseases 116 122
Other diseases 16 22
Total 187 219
All events were regarded as adverse events and were assigned to a disease
category.
doi:10.1371/journal.pone.0008394.t004
Table 5. Number of patients who received concomitant
treatments.
Treatments LV (56) Placebo (57)
Digestive tract and metabolism 32 36
Iron 17 11
Cardiovascular system 1 0
Dermatological 2 2
Corticosteroid 20 23
Systemic anti-infection agents 49 51
Non-steroid anti-inflammatory drugs 14 17
Analgesic drugs 22 27
Antiparasitic products 1 1
Respiratory system 33 40
Sensory organs 11 13
Rehabilitation 53 51
Total 255 272
doi:10.1371/journal.pone.0008394.t005
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study (3 months to 30 months). Our study population was
representative of the general DS population in terms of birth
weight, length, occipito-frontal circumference and malformation
frequency [2]. However, the age range studied may have been too
wide as major neurological acquisitions occur early in life and are
highly variable. This may have resulted in heterogeneity of the
population, potentially accounting, at least in part, for the negative
result of the intention-to-treat analysis.
Several clinical trials had reported negative results regarding the
effect of vitamin supplementation including folates [31,32,33,43].
The results of these studies, although carefully monitored, may be
challenged. Indeed, clinical trials on large DS populations are not
easy to perform, as centres specialising in DS treatment do not
have large patient cohorts. This is a major drawback of all studies.
By contrast, the most recent study [43] included 156 patients with
Down’s syndrome and a mix of 5 antioxidants or folinic acid was
given in a blinded manner. Folinic acid was not found to be active
on cognitive functions. However, we believe the daily dose of
folinic acid (0.1 mg vs. 1.060.3 mg/kg in our study) was too low
to be truly active. The negative results of our intent-to-treat
analysis may be due to our lack of expertise in managing large
trials. Psychometric analysis is a critical factor in such trials. When
we first wrote the protocol, we thought it would be possible for the
same psychometric examiner to carry out all three evaluations
(V1, V2 and V3). However, as some of our patients came from far
away and had limited flexibility in terms of appointments, it was
sometimes difficult for the same psychologist to carry out
assessments at the beginning and end of the study (12 months
later). As even well trained professionals may vary in terms of the
running of tests, we believe that analyses in which the same
psychologist carried out at least two of the tests (per protocol
analysis) are likely to be more accurate, although this violates the
intention-to-treat analysis protocol. These pitfalls should be
carefully avoided in subsequent studies, and the use of interna-
tionally validated scales would be required for international trials.
However such scales are not always available, may be complicated
to use, may result in young DS patients systematically obtaining
scores towards the bottom of the scale or may not be linear over
long periods. The Brunet-Lezine scale has several advantages: it is
well established, easy to use and reproducible. However, we will
probably use international scales, such as the Griffith’s scale in
future studies. Nevertheless, the development of reliable scales
remains a key issue.
The relationship between leucovorin and thyroxin treatment
was not expected, although thyroid status is known to be
important for the mental development of patients with trisomy
21. Several hypotheses may be proposed to explain the possible
synergistic effect of LV and thyroid treatment. The first hypothesis
is that the antioxidant effect of folinic acid may have been
amplified by the oxidative stress induced by thyroxin treatment.
Indeed, thyroid hormone has been shown to increase mitochon-
dria metabolism and thus production of reactive oxygen species
(particularly in patients with hypothyroidism) and to induce an
antioxidant imbalance [44,45,46]. Furthermore, thyroid hormone
has been shown to down regulate the expression of a gene involved
in the catabolism of free oxygen radicals, superoxide dismutase-1
[47]. All together, these facts may explain why thyroxin may have
stimulated the cognitive development of the children and how
folinic acid may have limited the thyroxin drawbacks linked to
oxidative stress.
The second hypothesis is that homocysteine, which is involved
in both the folate pathway and thyroid status, may play a key role
in the relationship between LV and thyroid treatment. Homocys-
teine is remethylated or leaves the cycle by being further
transformed by CBS (cataplerosis) (Figure 1). Thyroid hormones
probably induce the expression of certain genes, but these results
must be interpreted with caution, given the complexity of the
different metabolic pathways. Plasma total homocysteine (tHcy)
concentration is inversely correlated with thyroid hormone levels
[48,49] and returns to normal levels when euthyroidism is restored
[50,51]. Hypothyroid patients also have low plasma folate
concentrations, and folate supplementation in addition to thyroid
treatment is recommended [48]. A relationship between thyroid
status and folates has also been shown for methyl tetrahydrofolate
reductase (MTHFR) activation in humans and rats [52,53,54].
Some studies have reported that IQ is related to tHcy
concentrations in DS patients, and to polymorphisms of two
enzymes of the remethylation pathway—MTHFR (C677T) and a
transcobalamin (TCN C776G) [22]. Unfortunately, tHcy levels
and MTHFR, TCN2 and MTHFD1 polymorphisms were not
investigated in our patients. Future studies should consider these
factors, to improve our understanding of therapeutic mechanisms.
However, these findings suggest that homocysteine may play a
negative role in the neurons of DS patients alone or via its
metabolites [12,55].
The improvement of cognitive functions associated with LV
treatment may increase the autonomy of the DS population. If
maintained over time, it could increase quality of life and may
have economic implications. A follow-up study is planned for these
patients at the age of seven years, to check whether the LV-
induced enhancement of development is maintained over time.
The interaction between folates and thyroxin also requires
investigation. Further studies should also focus on the cofactors
identified in this trial. Despite technical difficulties, this trial
strongly suggests that the psychomotor development of DS
patients may be improved by treatments acting on metabolic
pathways. These encouraging results should lead to a search for
specific drugs targeting the metabolic disturbances induced by the
overexpression of chromosome 21 genes.
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